Utilisation des médicaments antiplaquettaires en pratique médicale courante

Sang Thrombose Vaisseaux

Volumn 8, Issue SPEC. ISS., 1996, Pages 22-32

  Dechavanne, M ^a   Wautier, J L ^a   Goudemand, J ^a   Lecompte, T ^a   De Moerloose, P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 3743081791     PISSN: 09997385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Hirsh J, Dalen JE, Fuster V, et al. Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects. Chest 1995 ; 108 : 247S-57S.
2. Antiplatelet trialists' collaboration. Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994 ; 308 : 81-106.
3. ISIS-2 (Second international study of infarct survival) collaborative group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17, 187 cases of suspected acute myocardial infarction. Lancet 1988 ; 2 : 349-60.
4. Antiplatelet trialists' collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988 ; 296 : 320-31.
5. Antiplatelets trialists' collaboration. II. Maintenance of vascular grafts of arterial patency by antiplatelet therapy. Br Med J 1994 ; 308 : 159-68.
6. Juul-Moller S, Edvardsson N, Jahnmatz B, et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992 ; 340 : 1421-5.
7. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990 ; 336 : 827-30.
8. Farrel B, Godwin J, Richards S, et al. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial : final results. J Neurol Neurosurg Psychiatry 1991 ; 54: 1044-54.
9. The SALT collaborative group. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991 ; 338 : 1345-9.
10. Clagett GP, Krupski C. Antithrombotic therapy in peripheral vascular disease. Chest 1995; 108: 431S-43S.
11. Levine HJ, Pauker SG, Eckman MH. Antithrombotic therapy in valvular heart diseases. Chest 1995 ; 108 : 360S-70S.
12. Stein PD, Alpert JS, Copeland JG, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1995 ; 108 : 424S-30S.
13. Albers GW. Atrial fibrillation and stroke: three new studies, three remaining questions. Arch Intern Med 1994 ; 154 : 1443-8.
14. The steering committee of the physicians' health study research group. Preliminary report: findings from the aspirin component of the physicians' health study. N Engl J Med 1988 ; 312 : 262-4.
15. Peto R, Gray R, Collins R, et al. Randomized trial of prophylactic daily aspirin in British male doctors. Br Med J 1988 ; 296 : 313-6.
16. Van Ganderen PJ, Michiels JJ, Van Strik R, et al. Platelet consumption in thrombocythemia complicated by erythromelalgia : reversal by aspirin. Tnromt Haemostas 1995 ; 73 : 210-4.
17. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995 ; 332 : 1132-6.
18. Davi G, Catalano I, Averna M, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus, N Engl J Med 1990 ; 332 : 1769-74.
19. ETDRS Investigators: Aspirin effects on mortality and morbidity in patients with diabetes mellitus: early treatment diabetic retinopathy study report 14. JAMA 1992 ; 268 : 1292-300.
20. CLASP (Collaborative low-dose aspirin study in pregnancy) collaborative group. CLASP: a randomized trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9'364 pregnant women. Lancet 1994 ; 346 : 619-29.
21. Italian study of aspirin in pregnancy. Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension. Lancet 1994 ; 341 : 396-400.
22. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 1995 ; 332 : 993-7.
23. Antiplatelet trialists' collaboration. Collaborative overview of randomized trials of antiplatelet therapy : III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Br Med J 1994 ; 308 : 235-43.
24. Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin : an overview of randomized controlled trials. Br J Clin Pharmacol 1993 ; 35 : 219-26.
25. Lindblad B, Persson NH, Takolander R, et al. Dose low-dose acetylasicylic acid prevent stroke after carotid surgery? A double-blind, placebocontrolled randomized trial. Stroke 1993 ; 24 : 1125-8.
26. The Dutch TIA trial study group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991 ; 325 : 1261-6.
27. Helqason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994 ; 24 : 2331-6.
28. Rodgers RPC, Levin J. A critical reappraisal of the bleeding time. Sem Thromb Haemostas 1990 ; 16 : 1-20.
29. Hafner J, de Moerloose P, Bounameaux H. Oral anticoagulation alone or in combination with aspirin : risks and benefits. VASA 1996 ; 25 : 1-12.
30. Turpie AG, Gent G, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart valve replacement. N Engl J Med 1993 ; 329 : 524-9.
31. McTavish DD, Faulds D, Goa KL. Ticlopidine: an updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs 1990 ; 40 : 238-59.
32. Schror K. The basic pharmacology of ticlopidine and clopidogrel. Platelets 1993 ; 4 : 27-36.
33. Hass WK, Easton JD, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989 ; 321 : 501-7.
34. Van Belle E, McFadden EP, Lablanche JM, et al. Two-prolonged antiplatelet therapy with aspirin and ticlopidine without systemic anticoagulation : an alternative therapeutic strategy after bailout stent implantation. Coronary Artery Disease 1995 ; 6 : 341-5.
35. Popma JJ, Coller BJ, Ohman EM, et al. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 1995 ; 108 : 486S-501S.
36. Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin versus aspirin alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996 ; 93 : 215-22.
37. Bertrand ME, Allain H, Lablanche JM. Results of randomized trial of ticlopidine versus placebo for prevention of acute closure and restenosis after coronary angioplasty : the TACT study. Circulation 1990 ; 82 : III-90.
38. Gent M, Blakely JA, Easton JD, et al. The Canadian American ticlopidine study (CATS) in thromboembolic stroke. Lancet 1989 ; ii : 1215-20.
39. Boissel JP, Peyrieux JC, Destors JM. Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lowerlimbs? Thromb Haemostas 1989 ; 62 : 681-5.
40. Janzon L, Bergqvist D, Boberg J, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication. Effects of ticlopidine. Results from STIMS, the Swedish ticlopidine multicentre study. J Intern Med 1990 ; 227 : 301-8.
41. Bergqvist D, Almgren B, Dickinson JP. Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: results from the Swedish Ticlopidine Study (STIMS). Eur J Vasc Endovasc Surg 1995 ; 10 : 69-76.
42. Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. Circulation 1990 ; 82 : 17-26.
43. TIMAD study group. Ticlopidine treatment reduces the progression of non proliferaticive diabetic retinopathy. Arch Ophthalmol 1990 ; 108 : 1577-83.
44. The DAMAD study group. Effect of aspirin alone one aspirin plus dipyridamole in early diabetic retinopamy. A multicenter randomized controlled study. Diatebes 1989 ; 38 : 491-8.
45. Limet R, David JL, Margotteaux P, et al. Prevention of aorto-coronary bypass graft occlusion: Beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double blind study. J Thorac Cardiovasc Surg 1987 ; 94 : 773-83.
46. Lecompte TP, Phan KP. Perioperative use of antiplatelet agent in cardiovascular surgery: assessment of the bleeding risk and management. In : Samama CM, ed. Hemostasis and thrombosis in cardiovascular surgery. Paris: Arnette Blackwell, 1993; 47-54.
47. Pitney WR, Nicol M, Dean S, Hickey A. Effect of flurbiprofen on bleeding time and platelets aggregation. Thromb Res 1978 ; 13 : 811-9.
48. Fornaro G, Rossi P, Mantica P, et al. Indobufen in the prevention of thromboembolic complications in patients with heart disease. Circulation 1993 ; 87 : 162-4.
49. The SINBA Group. Indobufen versus aspirin plus dipyridamole after coronary artery bypass surgery. Coron Artery Dis 1991 ; 2 : 897-906.
50. Rajah SM, Rees M, Walker D, et al. Effects of antiplatelet therapy with indobufen or aspirin-dipyridamole on graft patency 1 year after coronary artery bypass grafting. J Thor Cardiovase Surg 1994 ; 107 : 1146-53.
51. Fiessinger JN, Schäfer M. For the TOA study group Iloprost versus aspirin treatment for critical limb ischaemia of thromboangeitis obliteans. Lancet 1990 ; 335 : 555-7.
52. Grant SM, Goa KL. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 1992 ; 43 : 889-924.
53. Weite IJ, Califf RM, Ginsberg JS, et al. New antithrombotics. Chest 1995 ; 108 : 471S-85S.
54. EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994 ; 330 : 956-61.
55. Topol EJ, Califf RM, Weisman HF, et al. Randomized trial of coronary intervention with antibody against platelet anti IIb/IIIa integrin for reduction of clinical restenosis: results at 6 months: the EPIC investigators. Lancet 1994 ; 343 : 881-6.
56. Fergusson JJ. EPILOG and CAPTURE trials halted because of positive interim results. Circulation 1996 ; 93 : 637.